Purchase Order 36C24226P0193

The Department of Veterans Affairs Veterans Integrated Service Network 2 (VISN 2) awarded a firm fixed-price purchase order valued at $49,748.73 to Novocure Inc. on November 28, 2025, for transducers with a completion date of March 31, 2026. The contract does not utilize a set-aside designation. Novocure Inc., a foreign-owned medical device manufacturer specializing in Tumor Treating Fields (TTFields) cancer therapy technologies, will deliver these transducers to support its Optune system operations at VA facilities in the Portsmouth, NH area. This award represents a direct delivery under Novocure's existing Federal Supply Schedule contract with the VA VHA, valued at $28.85 million and running through October 31, 2027, which streamlines procurement of the company's FDA-approved cancer treatment technologies for veteran patients.

The transducer components are essential elements of Novocure's non-invasive Optune medical devices, which are approved for treating solid tumor cancers including glioblastoma and mesothelioma. As a specialized medical device supplier, Novocure operates as the prime contractor and does not employ subcontractors, delivering proprietary technologies directly to VA medical centers nationwide. This purchase order aligns with the VA's broader mission to expand veterans' access to cutting-edge cancer treatment options through streamlined acquisition vehicles.